

O-015 LONG-TERM CLINICAL AND ANGIOGRAPHIC OUTCOMES IN 140 PATIENTS WITH 166 CEREBRAL ANEURYSMS TREATED WITH THE PIPELINE EMBOLIZATION DEVICE: A MULTI-CENTER COHORT STUDY

¹J Delgado Almandoz, ²O Tenreiro-Picon, ¹Y Kayan, ¹J Fease, ¹J Scholz, ¹A Milner, ³M Mulder, ²A Tenreiro. ¹Neurointerventional Radiology, Abbott Northwestern Hospital, Minneapolis, MN; ²Neurointerventional Radiology, Clinica El Avila, Caracas, Venezuela, Bolivarian Republic of Venezuela; ³Critical Care Medicine, Abbott Northwestern Hospital, Minneapolis, MN

10.1136/neurintsurg-2016-012589.15

Purpose To examine long-term clinical and angiographic outcomes in a consecutive cohort of patients with cerebral aneurysms treated with the Pipeline Embolization Device (PED) in 2 referral centers.

Materials and methods We conducted a retrospective review of all patients with cerebral aneurysms treated with the PED at 2 referral medical centers between March 10th, 2011 and November 5th, 2015. Baseline patient and aneurysm characteristics, intra-operative, peri-operative and delayed complications were recorded. Aneurysm volumes in initial and follow-up angiographic studies were calculated using AngioCalc. Clinical outcomes were categorized using the modified Rankin Scale (mRS).

Results 140 patients underwent 150 PED procedures to treat 166 cerebral aneurysms during the study period. 109 patients were women (78%) and 31 men (22%). Mean age was 55 years (range 15–81 years). 87 aneurysms were incidental (52%), 39 recurrent (24%), 23 symptomatic (14%) and 17 ruptured (10%), 11 treated sub-acutely and 6 treated acutely). 22 aneurysms were fusiform (13%), 7 dissecting (4%) and 6 blister (4%). 125 aneurysms were located in the internal carotid (75%), 15 in the middle cerebral (9%), 10 in the anterior cerebral (6%), 10 in the vertebral (6%), 4 in the basilar (2%) and 2 in the posterior cerebral arteries (1%). Mean aneurysm size was 10.2 mm, mean neck was 6.4 mm, mean dome-to-neck ratio was 1.6. Mean number of PEDs deployed per aneurysm was 1.1. Adjunctive coiling was performed in 15 aneurysms (9%). The table summarizes the intra-operative, peri-operative and delayed complications, categorized by the first 75 and subsequent 75 PED procedures. There was a statistically-significant decrease in the rate of any intra-operative as well as disabling treatment-related complications between the first 75 and next 75 PED procedures. Similarly, there was a trend toward a decrease in treatment-related mortality between the first 75 and the next 75 PED procedures. Angiographic follow-up was obtained in 139 aneurysms (84%), with a mean time to last angiographic follow-up of 18.1 months. At last follow-up, 109 aneurysms were completely occluded (78.4%), 10 had near-complete occlusion ($\geq 90\%$ volume reduction, 7.2%), and 20 aneurysms had $<90\%$ volume reduction (14.4%, mean volume reduction 53%). 4 aneurysms were retreated (2.9%). Among the 16 aneurysms symptomatic from mass effect (10%), symptoms completely resolved in 8 patients (50%), improved in 3 patients (19%), remained unchanged in 3 patients (19%) and worsened in 2 patients (12%). There were 3 post-operative aneurysm ruptures (1.8%), 2 of which occurred in ruptured aneurysms treated acutely with the PED.

Conclusions The PED is an effective treatment for wide-neck cerebral aneurysms, with high long-term complete/near-complete aneurysm occlusion rates and low retreatment rates. The risk of intra-operative and disabling treatment-related

complications decreases significantly with increased experience in PED use and patient management.

Abstract O-015 Table 1 Complications in cerebral aneurysms treated with pipeline

	All 150 procedures (%)	First 75 procedures (%)	Next 75 procedures (%)	p-value*
Any Intra-Operative Complication	12 (8)	10 (13.3)	2 (2.7)	0.016
Resulting in mRS > 2	1 (0.7)	1 (1.3)	0	1
Any Peri-Operative Complication:	27 (18)	12 (16)	15 (20)	0.67
Resulting in mRS > 2	8 (5.3)	6 (8)	2 (2.7)	0.28
Any Delayed Complication:	6 (4)	4 (5.3)	2 (2.7)	0.68
Resulting in mRS > 2	1 (0.7)	1 (1.3)	0	1
Any Treatment-Related Complication Resulting in mRS > 2	10 (6.7)	8 (10.7)	2 (2.7)	0.049
Treatment-Related Mortality	5 (3.6)	4 (5.9)	1 (1.4)	0.19

*p-value for the difference between the first 75 and next 75 procedures using Fisher's exact test. mRS: Modified Rankin Scale. Peri-operative complication: occurring up to post-operative day 30. Delayed complication: occurring after post-operative day 30.

Disclosures J. Delgado Almandoz: 2; C; MedTronic Neurovascular. O. Tenreiro-Picon: None. Y. Kayan: 2; C; MedTronic Neurovascular. J. Fease: None. J. Scholz: None. A. Milner: None. M. Mulder: None. A. Tenreiro: None.


O-016 IN SITU TISSUE ENGINEERING: ENDOTHELIAL GROWTH PATTERNS AS A FUNCTION OF FLOW DIVERTER DESIGN

¹M Marosfoi, ¹E Langan, ²L Strittmatter, ¹K van der Marel, ³J Arends, ⁴S Loganathan, ²G Hendricks, ¹A Puri, ¹A Wakhloo, ¹M Gounis. ¹Radiology, University of Massachusetts, Worcester, MA; ²Cell Biology, University of Massachusetts, Worcester, MA; ³Preclinical Research, Stryker Neurovascular, Fremont, CA; ⁴Research and Development, Stryker Neurovascular, Fremont, CA

10.1136/neurintsurg-2016-012589.16

Purpose To identify progenitor cells involved in flow diverter (FD) endothelialization and to assess the impact of FD design on aneurysm occlusion and endothelialization patterns.

Materials and methods Sixteen complex, elastase induced aneurysms in white New Zealand rabbits were randomly treated with 2 different types of single-layer braided flow diverters made of cobalt-chrome alloys: Device-1 – 48 wires



Abstract O-016 Figure 1 Representative immunogold SEM results showing an endothelial progenitor cell attached to a wire of device-1 at 10 days from implant (left). High magnification image confirms gold staining of CD34 (arrowhead, right)

having 33 μm diameter and 145° braid angle and Device-2 – 72 wires having 32 μm diameter with a 115° braid angle. Each device had interwoven platinum wires for radio-opacity. The aneurysm occlusion rate was assessed during final DSA at 10, 20, 30 and 60 day ($n = 2$ per device per timepoint) using a 0–4 score scale.¹ Implanted vessels were analyzed with scanning electron microscopy (SEM) for tissue coverage and endothelialization (scored: 0–5 from no endothelial cells present, 0, to completely mature endothelial layer, 5) and immunogold labeling technique identifying CD 34+ progenitor cells.

Results Baseline characteristics (e.g., aneurysm size, neck size, PRU, parent vessel diameter) were not different between the two groups ($p > 0.1$). CD34 + endothelial progenitor cells (EPCs) were present on both devices (Figure 1) at the center of aneurysm neck and along the entirety of the devices at all timepoints. There was no significant difference in complete aneurysm occlusion rates between the devices; however, complete or near complete occlusion was more frequently observed in aneurysms with neck ≤ 4.2 mm ($p = 0.008$). The total tissue coverage over the surface of device-1 and device-2 was $72 \pm 17.4\%$ and $76.9 \pm 13.5\%$, respectively ($p > 0.05$). The endothelial cell growth over the surface was time dependent for device-2 (Spearman's $\rho = 0.86$, $p = 0.013$), but not device-1 (Spearman's $\rho = 0.59$, $p = 0.094$). Endothelialization score was marginally correlated with the distance from the aneurysm neck for device-1 (Spearman's $\rho = 1$, $p = 0.083$), but not for device-2 (Spearman's $\rho = 0.8$, $p = 0.33$).

Conclusion Our study supports the hypothesis that the bone marrow derived CD34+ progenitor cells contribute to flow diverter endothelialization and EPCs are present throughout the healing process up to 60 days. Although there was no difference in complete aneurysm occlusion, we have preliminary evidence of temporal and spatial dependence of endothelialization on FD design. Future FD designs can incorporate these analyzes during development to accelerate in situ tissue response to the scaffold.

REFERENCE

1 Darsaut TE, et al. *AJNR Am J Neuroradiol* 2012;**33**:2004–2009.


Disclosures M. Marosfoi: None. E. Langan: None. L. Strittmatter: None. K. van der Marel: None. J. Arends: 5; C; Stryker Neurovascular. S. Loganathan: 5; C; Stryker Neurovascular. G. Hendricks: None. A. Puri: 1; C; Stryker Neurovascular, Medtronic Neurovascular. 2; C; Codman Neurovascular, Medtronic Neurovascular, Stryker Neurovascular. A. Wakhloo: 2; C; Stryker Neurovascular. M. Gounis: 1; C; Stryker Neurovascular, Medtronic Neurovascular. 2; C; Stryker Neurovascular, Codman Neurovascular.

O-017 RECURRENT INTRACRANIAL VERTEBRAL ARTERY DISSECTING ANEURYSMS AFTER STENT-ASSISTED COIL EMBOLIZATION-A COMPUTATIONAL FLUID DYNAMIC ANALYSIS

J Liu, ¹L Jing, ¹Y Zhang, ¹Y Song, ¹Y Wang, ¹C Li, ¹Y Wang, ¹S Mu, ²N Paliwal, ²H Meng, ³I Linfante, ¹X Yang. ¹Department of Interventional Neuroradiology, Beijing Neurosurgical Institute and Beijing Tiantan Hospital, Beijing, China; ²Toshiba Stroke and Vascular Research Center, and Department of Mechanical and Aerospace Engineering, University at Buffalo, The State University of New York, Buffalo, NY; ³Miami Cardiac and Vascular Institute and Baptist Neuroscience Center, Miami, FL

10.1136/neurintsurg-2016-012589.17

Introduction Intracranial vertebral artery dissecting aneurysms (VADAs) tend to recur despite successful stent-assisted coil embolization (SACE). Computational fluid dynamic (CFD) can assess hemodynamic alterations in wall shear stress (WSS) and velocity in the aneurysmal wall. CFD has proven to be useful in evaluating aneurysmal formation, growth and rupture. Our aim was to evaluate the hemodynamic patterns of VADA's recurrence by CFD.



Abstract O-017 Figure 1